| [1] |
Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis[J].The Lancet, 2013, 381(9882): 2016-2023.
|
| [2] |
Weuve J, Hebert LE, Scherr PA, et al. Prevalence of Alzheimer disease in US states[J]. Epidemiology, 2015, 26(1): e4-e6.
|
| [3] |
Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association, 2015, 11(3): 332-384.
|
| [4] |
Burns A, Iliffe S. Alzheimer's disease[J]. BMJ, 2009, 338: b158.
|
| [5] |
Khachaturian ZS, Khachaturian AS, Thies W. The draft "National Plan" to address Alzheimer's disease-National Alzheimer's Project Act (NAPA)[J]. Alzheimers Dementia, 2012, 8(3): 234-236.
|
| [6] |
EUROPEAN COMMISSION. Implementation report on the Commission Communication on a European initiative on Alzheimer's disease and other dementias in EUROPEAN COMMISSION 2014 Brussels, 2014. [2016-01-15].
URL
|
| [7] |
Bianchetti A, Ranieri P, Margiotta A, et al. Pharmacological treatment of Alzheimer's disease[J]. Aging Clin Exp Res, 2006, 18(2): 158-162.
|
| [8] |
Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease[J]. N Engl J Med, 2013, 368(13): 1169-1171.
|
| [9] |
Gilman S, Koller M, Black RS, et al. Clinical effects of Aβimmunization (AN1792) in patients with AD in an interrupted trial[J]. Neurology, 2005, 64(9): 1553-1562.
|
| [10] |
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumabin mild-to-moderate Alzheimer's disease[J]. N Engl J Med, 2014, 370(4): 322-333.
|
| [11] |
Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease[J]. N Engl J Med, 2014, 370(4): 311-321.
|
| [12] |
Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease[J]. N Engl J Med, 2013, 369(4): 341-350.
|
| [13] |
Pharmaceutical Research and Manufacturers of America. ResearchingAlzheimer's Medicines:Setbacks and Stepping Stones, 2012. [2016-01-15].
URL
|
| [14] |
Use, C.f.M.P.f.H., Guideline on medicinal products for the treatment of Alzheimer's Disease and other dementias (Doc. Ref. CPMP/EWP/553/95 Rev. 1). London, European Medicines Agency, 2008.
|
| [15] |
Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014[J]. J Intern Med, 2014, 275(3): 251-283.
|
| [16] |
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13(6): 614-629.
|
| [17] |
Frisoni GB, Winblad B, O'Brien JT. Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use[J].Int Psychogeriatr, 2011, 23(08): 1191-1196.
|
| [18] |
彭丹涛，许贤豪，刘江红，等．简易智能精神状态检查量表检测老年期痴呆患者的应用探讨[J]．中国神经免疫学和神经病学杂志，2005，12(4): 187-190.
|
| [19] |
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state" : a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12(3): 189-198.
|
| [20] |
Arevalo-Rodriguez I, Smailagic N, Roqué I Figuls M, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev, 2015, 3: CD010783.
|
| [21] |
贾建平，王荫华，张振馨，等．中国痴呆与认知障碍诊治指南(三)：神经心理评估的量表选择[J]．中华医学杂志，2011，91(11): 735-741.
|
| [22] |
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53(4): 695-699.
|
| [23] |
Yu J, Li J, Huang X. The Beijing version of the montreal cognitive assessment as a brief screening tool for mild cognitive impairment: a community-based study[J]. BMC psychiatry, 2012, 12(1): 156.
|
| [24] |
Tan JP, Li N, Gao J, et al. Optimal cutoff scores for dementia and mild cognitive impairment of the montreal cognitive assessment among elderly and oldest-old chinese population[J]. J Alzheimers Dis, 2015, 43(4): 1403-1412.
|
| [25] |
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules[J]. Neurology, 1993, 43(11): 2412-2414.
|
| [26] |
Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia[J]. Am J Psychiatry, 1982, 139(9): 1136-1139.
|
| [27] |
Doraiswamy PM, Kaiser L, Bieber F, et al. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease[J]. Alzheimer Dis Assoc Disord, 2001, 15(4): 174-183.
|
| [28] |
Romero K, Ito K, Rogers JA, et al. The future is now: Model-based clinical trial design for Alzheimer's disease[J]. Clin Pharmacol Ther, 2015, 97(3): 210-214.
|
| [29] |
Li X, Xiao Z, Xiao S. Reliability and validity of Chinese version of Alzheimer's disease assessment scale-cognitive part[J]. Chinese Journal of Clinical Psychology, 2009, 17(5): 538-540.
|
| [30] |
Wang H, Yu X, Li S, et al. The cognitive subscale of Alzheimer's disease assessment scale, Chinese version in staging of Alzheimer disease[J]. Alzheimer Dis Assoc Disord, 2004, 18(4): 231-235.
|
| [31] |
Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial[J]. JAMA, 2004, 291(3): 317-324.
|
| [32] |
Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease[J]. Alzheimer Dis Assoc Disord, 1997, 11(Suppl): 51-56.
|
| [33] |
Tierney MC, Yao C, Kiss A, et al. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years[J]. Neurology, 2005, 64(11): 1853-1859.
|
| [34] |
Fox LS, Olin JT, Erblich J, et al. Severity of cognitive impairment in Alzheimer's disease affects list learning using the California Verbal Learning Test (CVLT) [J]. Int J Geriatr Psychiatry, 1998, 13(8): 544-549.
|
| [35] |
Crosson B, Novack TA, Trenerry MR, et al. California Verbal Learning Test (CVLT) performance in severely head-injured and neurologically normal adult males[J]. J Clin Exp Neuropsychol, 1988, 10(6): 754-768.
|
| [36] |
Grober E, Lipton RB, Hall C, et al. Memory impairment on free and cued selective reminding predicts dementia[J]. Neurology, 2000, 54(4): 827-832.
|
| [37] |
Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors[J]. CNS Drugs, 2013, 27(6): 469-478.
|
| [38] |
Winblad B, Gauthier S, Aström D, et al. Memantine benefits functional abilities in moderate to severe Alzheimer's disease[J]. J Nutr Health Aging, 2010, 14(9): 770-774.
|
| [39] |
Herrmann N, Li A, Lanctôt K. Lanctôt, Memantine in dementia: a review of the current evidence[J]. Expert Opin Pharmacother, 2011, 12(5): 787-800.
|
| [40] |
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living[J]. Gerontologist, 1969, 9(3): 179-186.
|
| [41] |
Gélinas I, Gauthier L, Mcintyre M, et al. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia[J]. Am J Occup Ther, 1999, 53(5): 471-481.
|
| [42] |
Juva K, Mäkelä M, Erkinjuntti T, et al. Functional assessment scales in detecting dementia[J]. Age and ageing, 1997, 26(5): 393-400.
|
| [43] |
Bicket MC, Samus QM, McNabney M, et al. The physical environment influences neuropsychiatric symptoms and other outcomes in assisted living residents[J]. Int J Geriatr Psychiatry, 2010, 25(10): 1044-1054.
|
| [44] |
Lawton MP. Quality of life in Alzheimer disease[J]. Alzheimer Dis Assoc Disord, 1994, 8(Suppl): 138-150.
|
| [45] |
Lehrner J, Kalchmayr R, Serles W, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients[J]. Seizure, 1999, 8(2): 88-92.
|
| [46] |
Mok CC, Siu AM, Chan WC, et al. Functional disabilities profile of Chinese elderly people with Alzheimer's disease-a validation study on the Chinese version of the disability assessment for dementia[J]. Dement Geriatr Cogn Disord, 2005, 20(2-3): 112-119.
|
| [47] |
Lin Kiat Yap P, Yen Ni Goh J, Henderson LM, et al. How do Chinese patients with dementia rate their own quality of life[J]? Int Psychogeriatr, 2008, 20(3): 482-493.
|
| [48] |
Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease[J]. Neurology, 2001, 57(4): 613-620.
|
| [49] |
Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change[J]. Alzheimer Dis Assoc Disord, 1997, 11(Suppl 2): 22-32.
|
| [50] |
O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using clinical dementia rating scale sum of boxes scores: a texas Alzheimer's research consortium study[J]. Arch Neurol, 2008, 65(8): 1091-1095.
|
| [51] |
Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease–a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)[J]. Arch Med Sci, 2011, 7(1): 102-111.
|
| [52] |
Coley N, Andrieu S, Jaros M, et al. Suitability of the clinical dementia rating-sum of boxes as a single primary endpoint for Alzheimer's disease trials[J]. Alzheimers Dement, 2011, 7(6): 602-610.e2.
|
| [53] |
Wimo A, Jonsson L, Zbrozek A. The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia[J]. J Nutr Health Aging, 2010, 14(8): 685-690.
|
| [54] |
George LK, Gwyther LP. Caregiver weil-being: a multidimensional examination of family caregivers of demented adults[J]. Gerontologist, 1986, 26(3): 253-259.
|
| [55] |
Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease[J]. Lancet Neurol, 2003, 2(10): 605-613.
|
| [56] |
Humpel C. Identifying and validating biomarkers for Alzheimer's disease[J]. Trends Biotechnol, 2011, 29(1): 26-32.
|
| [57] |
Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study[J].Lancet Neurol, 2006, 5(3): 228-234.
|
| [58] |
BlennowK. Cerebrospinal fluid protein biomarkers for Alzheimer's disease[J]. NeuroRx, 2004, 1(2): 213-225.
|
| [59] |
Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias[J]. Mol Psychiatry, 2003, 8(3): 343-347.
|
| [60] |
Bürger née Buch K, Padberg F, Nolde T, et al. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls[J]. Neurosci Lett, 1999, 277(1): 21-24.
|
| [61] |
Buerger K, Ewers M, Pirttilä T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease[J]. Brain, 2006, 129(11): 3035-3041.
|
| [62] |
Parnetti L, Lanari A, Silvestrelli G, et al. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers[J]. Mech Ageing Dev, 2006, 127(2): 129-132.
|
| [63] |
Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease[J]. Annals of neurology, 2001, 50(2): 150-156.
|
| [64] |
Babić M, Svob Štrac D, Mück-Šeler D, et al. Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease[J]. Croat Med J, 2014, 55(4): 347-365.
|
| [65] |
Sultana R, Poon HF, Cai J, et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach[J]. Neurobiol Dis, 2006, 22(1): 76-87.
|
| [66] |
Sinem F, Dildar K, Gökhan E, et al. The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy[J]. Curr Alzheimer Res, 2010, 7(5): 463-469.
|
| [67] |
Tarditi A, Caricasole A, Terstappen G. Terstappen, Therapeutic targets for Alzheimer's disease[J]. Expert Opin Ther Targets, 2009, 13(5): 551-567.
|
| [68] |
Kankaanpää J, Turunen SP, Moilanen V, et al. Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease[J]. Neurobiol Dis, 2009, 33(3): 467-472.
|
| [69] |
Jack CR Jr, Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment[J]. Neurology, 2008, 70(19 Part 2): 1740-1752.
|
| [70] |
Johnson KA, Fox NC, Sperling RA, et al. Brain imaging in Alzheimer disease[J]. Cold Spring Harb Perspect Med, 2012, 2(4): a006213.
|
| [71] |
Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET[J]. Neuroimage, 2002, 17(1): 302-316.
|
| [72] |
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease report of the NINCDS‐ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease[J]. Neurology, 1984, 34(7): 939-939.
|
| [73] |
Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia[J]. Arch Neurol, 1975, 32(9): 632-637.
|
| [74] |
Brink TL, Jerom A, Yesavage MD, et al. Screening tests for geriatric depression[J]. Clin Gerontol, 1982, 1(1): 37-43.
|
| [75] |
Gusmano M. End-of-life care for patients with dementia in the United States: institutional realities[J]. Health Econ Policy Law, 2012, 7(4): 485-498.
|
| [76] |
Golan OG, Marcus EL. Should we provide life-sustaining treatments to patients with permanent loss of cognitive capacities[J]?Rambam Maimonides Med J, 2012, 3(3): e0018.
|